loading...| Preferred Name | rabeprazole sodium | |
| Synonyms |
Aciphex Rablet Pariet |
|
| Definitions |
The sodium salt of the prodrug rabeprazole, a substituted benzimidazole proton pump inhibitor, with potential anti-ulcer activity. After protonation, accumulation, and transformation to the active sulfenamide within the acidic environment of gastric parietal cells, rabeprazole selectively and irreversibly binds to and inhibits the H+, K+ATPase (hydrogen-potassium adenosine triphosphatase) enzyme system located on the parietal cell secretory surface, inhibiting gastric acid secretion. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C29410" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C29410" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000641009 |
|
| altLabel |
Aciphex Rablet Pariet |
|
| cui |
C2825309 C0875952 C0732574 C0732569 |
|
| DATE FIRST PUBLISHED |
2009-04-17 |
|
| Date last modified |
2009-08-24 |
|
| definition |
The sodium salt of the prodrug rabeprazole, a substituted benzimidazole proton pump inhibitor, with potential anti-ulcer activity. After protonation, accumulation, and transformation to the active sulfenamide within the acidic environment of gastric parietal cells, rabeprazole selectively and irreversibly binds to and inhibits the H+, K+ATPase (hydrogen-potassium adenosine triphosphatase) enzyme system located on the parietal cell secretory surface, inhibiting gastric acid secretion. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C29410" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C29410" NCI Thesaurus) |
|
| LT |
TRD |
|
| NCI ID |
C29410 |
|
| notation |
CDR0000641009 |
|
| ORIG STY |
Drug/agent |
|
| prefLabel |
rabeprazole sodium |
|
| tui |
T109 T121 |